TR200401952T4 - Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı - Google Patents

Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı

Info

Publication number
TR200401952T4
TR200401952T4 TR2004/01952T TR200401952T TR200401952T4 TR 200401952 T4 TR200401952 T4 TR 200401952T4 TR 2004/01952 T TR2004/01952 T TR 2004/01952T TR 200401952 T TR200401952 T TR 200401952T TR 200401952 T4 TR200401952 T4 TR 200401952T4
Authority
TR
Turkey
Prior art keywords
hyaluronidase
prophylaxis
treatment
cardiovascular diseases
cardiac
Prior art date
Application number
TR2004/01952T
Other languages
English (en)
Inventor
Burgard Gunther
Cullmann Dieter
Original Assignee
Burgard Gunther
Cullmann Dieter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7644022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200401952(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Burgard Gunther, Cullmann Dieter filed Critical Burgard Gunther
Publication of TR200401952T4 publication Critical patent/TR200401952T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bulus, kalp dolasim rahatsizliklarinin profilaksisi ve/veya tedavisi için hiyaluronidaz enziminin günlük asgari 6000 birimlik bir dozajda kullanilmasina iliskindir, ki burada hiyaluronidaz i.v. olarak asgari 4 haftalik bir zaman araliginda verilir. Hiyaluronidaz özellikle koroner kalp rahatsizliginin ttedavisiyle kalp enfartüsü tehlikesi altinda olan hastalarin profilaksisi için uygundur.
TR2004/01952T 2000-05-29 2001-05-25 Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı TR200401952T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10026666A DE10026666A1 (de) 2000-05-29 2000-05-29 Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen

Publications (1)

Publication Number Publication Date
TR200401952T4 true TR200401952T4 (tr) 2004-09-21

Family

ID=7644022

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01952T TR200401952T4 (tr) 2000-05-29 2001-05-25 Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı

Country Status (8)

Country Link
US (2) US20050249717A1 (tr)
EP (2) EP1284749B1 (tr)
AT (2) ATE271881T1 (tr)
CA (1) CA2411233C (tr)
DE (2) DE10026666A1 (tr)
ES (2) ES2223842T3 (tr)
TR (1) TR200401952T4 (tr)
WO (1) WO2001091785A2 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8200466B2 (en) 2008-07-21 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Method for tuning patient-specific cardiovascular simulations
EP2177227B1 (en) * 2008-10-14 2013-03-20 Burgard, Gunter, Dr. med. Use of hyaluronidase for the prevention or treatment of arterial hypertension.
US9405886B2 (en) 2009-03-17 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Method for determining cardiovascular information
EP2266638A3 (de) * 2009-06-25 2014-08-13 Biotronik VI Patent AG Biokorrodierbares Implantat mit einer aktiven Beschichtung
US8315812B2 (en) 2010-08-12 2012-11-20 Heartflow, Inc. Method and system for patient-specific modeling of blood flow
US10162932B2 (en) 2011-11-10 2018-12-25 Siemens Healthcare Gmbh Method and system for multi-scale anatomical and functional modeling of coronary circulation
ITMI20130992A1 (it) 2013-06-17 2014-12-18 Fidia Farmaceutici Ialuronidasi batterica e metodo per la sua produzione
WO2022251645A1 (en) 2021-05-27 2022-12-01 Steiner Ventures Llc Hyaluronidase composition for intravenous administration and method of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410531A (en) * 1980-12-08 1983-10-18 Biorex Laboratories Limited Enzyme derived from hyaluronidase
NL8102880A (nl) * 1981-06-16 1983-01-17 Siegfried Willem Bok Farmaceutisch preparaat.
US4473621A (en) * 1983-07-19 1984-09-25 Johnson Matthey Limited Cadmium free gold alloys
IT1177874B (it) * 1984-07-04 1987-08-26 Sigma Tau Ind Farmaceuti Estere della acetil carnitina,procedimenti per la sua preparazione e composizioni farmaceutiche che lo contengono
DE19501378A1 (de) * 1995-01-18 1996-08-08 Heinz Dieter Cullmann Behandlung von Herz-Kreislauf-Erkrankungen
SE512633C2 (sv) * 1997-07-09 2000-04-17 Cecilia Johnsson Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat

Also Published As

Publication number Publication date
DE10026666A1 (de) 2001-12-20
EP1284749A2 (de) 2003-02-26
US20080124316A1 (en) 2008-05-29
EP1447090A2 (de) 2004-08-18
ATE534399T1 (de) 2011-12-15
WO2001091785A2 (de) 2001-12-06
EP1447090B1 (de) 2011-11-23
CA2411233C (en) 2009-09-15
ES2223842T3 (es) 2005-03-01
CA2411233A1 (en) 2001-12-06
DE50103012D1 (de) 2004-09-02
ES2374619T3 (es) 2012-02-20
EP1284749B1 (de) 2004-07-28
WO2001091785A3 (de) 2002-03-28
US20050249717A1 (en) 2005-11-10
EP1447090A3 (de) 2004-09-08
EP1447090B8 (de) 2012-02-22
ATE271881T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
SE9702860D0 (sv) New use
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE60134403D1 (de) Behandlung des akuten koronaren syndroms mit glp-1
BRPI0011640B8 (pt) ácidos aldônicos de oligossacarídeo e seu uso tópico
BR0014912A (pt) Tratamento de distúrbios do sono usando desloratadina
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
KR960702318A (ko) 근육 질병 및 장애의 치료방법
NZ334550A (en) Use of sibutramine analogues to lower lipid levels
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60234619D1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
TR200401952T4 (tr) Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
BR9810394A (pt) Azapeptìdeos cìclicos
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
Silver et al. Fluvoxamine augmentation for clozapine-resistant schizophrenia.
IT1274699B (it) Estratto vegetale contro le ustioni
DE60017136D1 (de) Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat
SE0101328D0 (sv) Therapeutic treatment
DE602004027515D1 (de) Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz
EP1311486A4 (en) APPLICATIONS OF THALIPORPHIN OR DERIVATIVES THEREOF IN THE TREATMENT OF CARDIAC DISEASES AND THE PREPARATION THEREOF
FR2822070B1 (fr) Utilisation d'un derive de biguanide et d'une pyrimidine pour la fabrication d'une composition de soin cosmetique
RU2000102172A (ru) Способ дозировки физических нагрузок по объему и интенсивности в лечебной и оздоровительной физкультуре
RU94002571A (ru) Способ раннего определения остаточной работоспособности у больных, перенесших инфаркт миокарда